Home > Oncology > ASCO 2019 > Sarcoma > Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint

Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint

Presented By
Dr William D. Tap, Memorial Sloan Kettering Cancer Centre, USA
Conference
ASCO 2019
Trial
Phase 3, ANNOUNCE
Featured video: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). [embed]https://medicomnl.s3.eu-central-1.amazonaws.com/video/asco2019/Tap.mp4[/embed]   Medical writer: Tim Donald, ELS The ANNOUNCE trial, assessing the overall survival (OS) benefit of olaratumab in patients with advanced soft tissue sarcoma (STS), failed to meet its dual primary endpoint of OS in all STS histologies or in a subset of patients with leiomyosarcoma (LMS), according to a Late-Breaking Abstract (Abstract LBA3) presented at the June 2 Plenary Session. William D. Tap, MD, of Memorial Sloan Kettering Cancer Centre, presented the study data. Dr. Tap explained that, after the data readout from this study, the trial sponsor and global regulatory agencies recommended that no...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on